-
2024-518138-10-00
4
Patients with DMMR and/or MSI metastatic colorectal cancer
-
2024-518139-12-00
4
locally advanced or metastatic Pancreatic ductal adenocarcinoma
-
2024-518225-15-00
4
Myelofibrosis
-
2024-518437-28-00
5
Sickle cell disease
-
2024-518835-13-00
5
Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar),
-
2024-519246-75-01
4
Patients With Muscle-Invasive Bladder Cancer
-
2024-519298-21-00
5
Cancer-Associated Thrombosis (CAT).
-
2024-519504-27-00
5
Relapsed Refractory Multiple Myeloma
-
2024-519753-11-00
4
Resectable borderline pancreatic adenocarcinoma
-
2024-520414-21-00
5
Adult patients with a LVOS with large core within 9 hours of symptoms
-
2025-520632-42-00
5
axial or predominantly axial SpA with or without psoriasis
-
2025-520976-25-00
4
Relapsed/refractory multiple myeloma
-
2025-521090-14-00
4
Patients with relapsed/refractory symptomatic multiple myeloma (MM)
-
2025-521113-13-00
10
Early Parkinson’s Disease
-
2025-521199-80-00
4
Patients with previously untreated symptomatic chronic lymphocytic leu
-
2025-521317-50-00
5
Cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs)
-
2025-521587-35-00
5
Metastatic colorectal cancer
-
2025-521619-37-00
5
Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
-
2025-521696-31-00
6
HR+, HER2- breast cancer at high risk of recurrence
-
2025-522138-29-00
4
Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with n
-
2025-522193-37-00
5
Septic arthritis
-
2025-522817-50-00
6
Severe pain
-
2025-522904-26-00
3
Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephri
-
2025-522983-33-00
5
Chronic rhinosinusitis with nasal polyps